Database of CDX Models

To facilitate preclinical in vivo PD/PK and toxicological studies as well as in vivo efficacy evaluation of potential cancer immunotherapies, Creative Biolabs has established over 200 validated and well-characterized CDX models as well as luciferase-labeled CDX models for your choice. Our broad range of cell lines ensure a large variety of research options for your candidates.

Solid Tumor CDX Models

Type Tumor Cell Line
Adrenal H295R
■ Brain Cancer LN-229, SF-295, SK-N-AS, U87 MG, U251
■ Breast Cancer 2LMP, 4T1, Bcap-37, BT20, BT474, DU4475, EMT6, HCC-70, HCC-1806, HCC-1954, JIMT-1, KPL-4, MCF-7, MCF-7-luc, MDA-MB-157, MDA-MB-231, MDA-MB-231-luc, MDA-MB-453, MDA-MB-468, MDA-N, Mx-1, SKBr-3, SUM159, T47D, ZR-75-1, ZR-75-30
■ Bladder Cancer BFTC905, HT-1197, HT-1376, J82, RT4, SCaBER, SW780, 5637, T24, UM-UC3
■ Bone Cancer U-2 OS
■ Cervical Carcinoma AN3 CA, ECC-1, HEC-1-A, ME-180, MFE-280, Hela, Hela-luc, KB-3-1
■ Colorectal Cancer CL-34, Colon137, COLO 201, COLO 205, COLO 320 DM, CT-26, CW-2, DLD-1, HCT-15, HCT-8, HT-29, HT-29-luc, HCT 116, HCT116 P53 K0(-/-), KM12, LoVo, LS-174T, LS-180, LS411N, LS1034, NCI-H716, RKO, SW48, SW403, SW480, SW620, SW837, WiDr
■ Endometrium Cancer HEC-1B
■ Epidermoid Carcinoma A-431
■ Gallbladder Carcinoma Mz-ChA-1, Mz-ChA-2, Wittier
■ Gastric Carcinoma AGS, AGS-luc, BGC-823, HGC-27, Hs746T, MGC-803, MKN-1, MKN-28, MKN-45, MKN-45-luc, NCI-N87, NUGC-4, NUGC-4-luc, SCH, SGC-7901, SNU-5, SNU-16, SNU-16-luc, Hs 746T
■ Glioma LN-229, U-87 MG, U-87 MG-luc, U-373, U-343
■ Head and neck Cancer CRL-1624, FaDu, KB
■ Liver Cancer Bel-7402, HCCLM3, HCCLM3-luc, Hep3B2.1-7, Hep3B, Hep3B-luc, HepG 2, HepG 2-luc, HuH-7, PLC/PRF/5, SNU-398, QGY-7703, SK-HEP-1, SMMC-7721
■ Lung Cancer 95-D, A-427, A549, A549-luc, Calu-1, Calu-3, Calu-6, COR-L23, DMS114, H23, H69, H82, H211, H510, H526, H1299, H1975, H226, H292, H2171, H358, H441, H460, H520, H522, H647, H727, H810, H1581, H1650, H1792, H1993, H2009, H2030, H2228, H358, HCC-15, HCC-44, HCC-827, KLN205, LL/2, LLC1, MSTO-211H, NCl-H69, NCl-H146, NCl-H209, NCI-H226, NCI-H446, NCI-H460, NCI-H466, NCI-H520, NCI-H522, NCI-H526, NCl-H720, NCl-H1155, NCI-H1688, NCl-H1770, NCI-H1781, NCI-H1975,  NCI-H1963, NCI-H1975-luc, NCl-H2106, NCI-H2122, NCI-H2126, NCI-H2228, PC-10, QG-56, SHP-77, SK-MES-1, SW1573
■ Melanoma A2058, A375, A375-luc, B16, C32, CHL-1, COLO 800, HMCB, IGR-1, IGR-37, M-13, MDA-MB-435s, MeWo, SK-MEL-5, SK-MEL-30, UACC-62, WM98-1
■ Mesothelioma MSTO-211H
■ Nasopharyngeal Carcinoma S18, S26
■ Neuroblastoma IMR5-75, Kelly, SK-N-MC, SK-N-SH, SKNAS
■ Ovarian Cancer A2780, A2780l-luc, ES-2, HOC-22, HO-8910PM, PA-1, IGR0V1, OV-90, OVCAR-3, OVCAR-5, OVCAR-8/ADR, SK-OV-3, TOV-21G
■ Pancreatic Cancer AsPC-1, BxPc-3, BxPc-3-luc, Capan-1, Capan-2, CFPAC-1, HPAC, HPAF II, Hup-T3, KP4, MIA, MIA-luc, MiaPaCa-2, PaCa-2, PaCa-2-luc, PANC-1, Patu-8902, PSN-1
■ Prostate Cancer 22Rv.1, CL-1, DU 145, LNCaP clone FGC, PC3, PC-3M-luc, VCaP
■ Renal Carcinoma A498, ACHN, Caki-1, Caki-2, 786-O, 786-O-luc, G-401, G-402, OS-RC-2, RENCA
■ Rhabdomyosarcoma A-673
■ Sarcoma HT-1080, MG-63, RD-ES, SJSA-1, S-180
■ Skin Cancer Clone M3
■ Thyroid Cancer 8505C, FTC-238, K1
■ Uterine ECC-1, HEC-1-A, HEC-1-B, MFE-280
■ Vulva Cancer A-431

Hematological Malignancies CDX Models

Type Tumor Cell Line
■ Acute Lymphoblastic Leukemia KARPAS-299, MOLM-13, MOLT-4, NALM-6, Jurkat, E6-1, CCRF-CEM
■ Acute Monocytic Leukemia U937, THP-1, MV4-11, MV4-11-luc
■ Acute Myeloid Leukemia EOL-1, HL-60, KG-1, MV4-11
■ Acute Myeloblastic Leukemia Kasumi-1, Kasumi-3(CD33+)
■ Acute Promyelocytic Leukemia HL-60
■ Chronic Myeloid Leukemia K-562, K-562-luc
■ Eosinophilic Leukemia EOL-1
■ Erythro Leukemia TF-1
■ Histiocytic Lymphoma U-937
■ Megakaryoblastic Leukemia SET-2
■ Multiple Myeloma H929, KMS-11, KMS-26, KMS-12-BM, OPM-2, RPMI 8226, SK-MM-2, 8226-luc, ARH-77, ML-2
■ Non-Hodgkin Lymphoma DoHH-2, Daudi, Farage, Granta 519, JEKO-1, KARPAS-299, Namalwa, Raji, Raji-luc, Ramos, REC-1, RL, SU-DHL-1, SU-DHL-4, WSU-DLCL2
■ Lymphoma (B-cell) Mino, Namalwa

With experienced scientists and substantial breadth of services, Creative Biolabs can assist in selecting the most appropriate CDX model to fit your candidates and cancer type. Customized CDX models are also available upon request. Please contact us for detailed information, and we are looking forward to working with you.

For Research Use Only | Not For Clinical Use

Online Inquiry
Copyright © 2024 Creative Biolabs. All Rights Reserved.
ISO 9001 Certified - Creative Biolabs Quality Management System.